JP Morgan analyst Caroline Pocher initiates coverage on Savara (NASDAQ:SVRA) with a Overweight ra

U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led

BlackRock Inc. acquired a new position in Savara Inc. (NASDAQ: SVRA) in the undefined quarter, accor

Algert Global LLC boosted its position in Savara Inc. (NASDAQ: SVRA) by 53.7% during the undefined q

Deutsche Bank AG purchased a new position in Savara Inc. (NASDAQ: SVRA) during the second quarter, a

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory d

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical compan

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical compan

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consens

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded

394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted ave

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha

Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, wit

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo

-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consens

-- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (B

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare

U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some

This morning 279 companies reached new 52-week highs.

Gainers

Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its C

144 Biggest Movers From Friday

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Tuesday

Stocks That Hit 52-Week Lows Of Monday

Stocks That Hit 52-Week Lows On Friday

New 52-Week Lows For Monday Morning

Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018